The metabolism-modulating activity of IL-17 signaling in health and disease

Rami Bechara, Mandy J. McGeachy, and Sarah L. Gaffen

IL-17 was discovered nearly 30 yr ago, but it has only been recently appreciated that a key function of this cytokine is to orchestrate cellular and organismal metabolism. Indeed, metabolic regulation is integrated into both the physiological and the pathogenic aspects of IL-17 responses. Thus, understanding the interplay between IL-17 and downstream metabolic processes could ultimately inform therapeutic opportunities for diseases involving IL-17, including some not traditionally linked to this cytokine pathway. Here, we discuss the emerging pathophysiological roles of IL-17 related to cellular and organismal metabolism, including metabolic regulation of IL-17 signal transduction.

Introduction

IL-17A, referred to here as IL-17, is the founding cytokine of IL-17 family that includes five other members, IL-17B–F (Monin and Gaffen, 2018). IL-17 is best known as a host-defensive cytokine at barrier mucosal tissues, with essential roles in immunity to fungi and other extracellular pathogens (Conti and Gaffen, 2010; Conti et al., 2009; Conti et al., 2016; Verma et al., 2017). IL-17 also drives inflammation in a variety of autoimmune pathologies (McGeachy et al., 2019; Veldhoen, 2017). Consequently, we have witnessed an effective application of IL-17/Th17 cell basic biology research discoveries to treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, etc. Additional drugs targeting the IL-17/Th17 cell pathway are in preclinical development (Prinz et al., 2020; Vitiello and Miller, 2020; McGeachy et al., 2019). Nevertheless, surprising new aspects of IL-17 biology continue to be discovered, indicating that our overall understanding of this cytokine system remains incomplete.

The metabolism-modulating activity of IL-17 is a relatively new feature of the events driven by this cytokine (Fig. 1). An intimate association between the immune and metabolic systems has emerged on many fronts, especially studies of metabolic syndrome where inflammatory cytokines from adipose tissue are linked to insulin resistance and related impairments (Makowski et al., 2020; Hotamisligil et al., 1993; Mathis and Shoelson, 2011). Paralleling immune regulation of the metabolic system, metabolism of immune cells themselves is highly regulated. “Immunometabolism” refers to two complementary facets of these interactions. The first relates to cellular metabolism, i.e., how metabolic regulation within immune cells leads to different cell fates and function (e.g., activation, proliferation, and differentiation; Gaber et al., 2017; O’Neill et al., 2016). The second focuses on the effect of inflammation and immune responses on the control of systemic metabolism (e.g., adipogenesis; Mathis, 2019; Troha and Ayres, 2020; Man et al., 2017; Lee et al., 2018; Hotamisligil, 2017a). Therefore, this fusion between immunity and metabolism has broadened our understanding of connections between autoimmune and metabolic diseases.

In mediating immunity to infections, IL-17 is expressed only transiently. However, in several chronic inflammatory and autoimmune diseases, IL-17 persists long term, and its capacity to influence metabolic syndrome may have severe consequences (McGeachy et al., 2019). In both settings, growing literature points to a role for IL-17 in cellular and organismal metabolism. At a cellular level, IL-17–mediated metabolic regulation promotes cell proliferation, a process that has been described in epithelial cells, keratinocytes, and stem cells to coordinate tissue repair and wound healing (Lee et al., 2015; Song et al., 2015; MacLeod et al., 2013; Chen et al., 2019). In addition, IL-17 promotes proliferation and survival of synovial fibroblasts (SFs; Kim et al., 2017) and fibroblastic reticular cells (FRCs; Majumder et al., 2019), which support IL-17–mediated inflammation in arthritis and models of multiple sclerosis, among other conditions (Yu et al., 2018; Majumder et al., 2019; Kim et al., 2017). Moreover, certain cellular metabolites (e.g., itaconate; O’Neill and Artyomov, 2019), influence IL-17 signal transduction. At the organismal level, IL-17 impacts adipogenesis, thermogenesis, and fibrosis (Ahmed and Gaffen, 2010; Kohlgruber et al., 2018; Hu et al., 2020; Okamoto et al., 2012; Madhur et al., 2010; Wilson et al., 2010). Elevated levels of IL-17 are detected in numerous metabolic disease settings, including obesity (Sumarac-Dumanovic et al., 2009; Winer et al., 2009), diabetes (Arababadi et al., 2010; Marwaha et al., 2010), and...
osteoporosis (Zhang et al., 2015). Moreover, some IL-17–driven conditions (e.g., psoriasis) constitute a major risk for metabolic syndrome (Davidovici et al., 2010; Azfar and Gelfand, 2008).

In this review, we outline the current view of metabolic pathways that underlie IL-17 function, including metabolic patterns of IL-17–target cells to metabolic homeostasis or diseases mediated by an IL-17 response. Changes in cellular metabolism that contribute to Th17 cell differentiation are also discussed.

The immunometabolic response in immune and structural cells
The immune system needs to be poised to respond rapidly to harmful triggers and continuously adapt to diverse environments and, hence, requires immediately available energy sources. At the same time, the potentially damaging effects of resulting metabolites must be avoided (Hotamisligil, 2017b; Wang et al., 2019; Buck et al., 2017). Hence, cells rely on a balance between catabolism and anabolism, which are dependent on various metabolic substrates, such as glucose, fatty acids, and amino acids (Wang et al., 2019). These substrates are involved in at least six major metabolic pathways: glycolysis, tricarboxylic acid (TCA) cycle, pentose phosphate pathway, fatty acid oxidation (FAO), fatty acid synthesis (FAS), and amino acid metabolism (Fig. 2 A; O’Neill et al., 2016). Although diverse in terms of intracellular metabolites that are generated, these pathways are interconnected and coregulated. For example, the FAS pathway, required for cellular proliferation, requires the availability of intermediate metabolites generated during glycolysis and the TCA cycle (Fig. 2 A; O’Neill et al., 2016). Proinflammatory stimuli are usually mitogenic, activating anabolic pathways (e.g., glycolysis and FAS) that lead to proliferation and differentiation (Wang et al., 2019). Alternatively, anti-inflammatory signals drive catabolic pathways (e.g., FAO) and promote cellular quiescence (Wang et al., 2019).

The fast-paced literature on immunometabolism in the past few years has revealed requirements for specific metabolic events in all immune cells: macrophages (O’Neill and Pearce, 2016; Covarrubias et al., 2015; Russell et al., 2019), neutrophils (Injarabian et al., 2019), dendritic cells (O’Neill and Pearce, 2016; Pearce and Everts, 2015), natural killer cells (O’Brien and Finlay, 2019), and T cells (Pearce et al., 2013; Bantug et al., 2018; Man and Kallies, 2015). The status of cellular metabolism governs the types of cytokines produced by immune cells and, consequently, the ensuing immune response. This concept was illustrated in macrophages, where M1 cells are highly glycolytic, whereas M2 macrophages rely largely on oxidative phosphorylation (O’Neill and Pearce, 2016; Russell et al., 2019; Vats et al., 2006). A recent study showed that subsets of γδ-T cells differ in their metabolic signatures and are influenced by the obesity status of the host (Lopes et al., 2021). Hence, metabolic requirements critically dictate cell fate and function.

With regard to the IL-17 pathway, immunometabolism has been most extensively studied in Th17 cells. However, non-hematopoietic cells, the main targets of IL-17 signaling, are less well defined in terms of immunometabolic events (Monin and Gaffen, 2018; McGaehy et al., 2019). The sensitivity of IL-17–target cells is thought to be mainly due to restricted expression of the essential IL-17RC subunit. With the exception of in vitro–differentiated Th17 cells (Chong et al., 2020), IL-17RC is generally expressed at low or undetectable levels in hematopoietic cells (Kuestner et al., 2007; Ishigame et al., 2009). IL-17–responsive cells reside in highly diverse tissues and organs, and hence, it is not surprising that each cell type has distinct metabolism and nutrient usage. Recently, advances in single-cell transcriptomic technologies have uncovered the heterogeneity of mesenchymal and epithelial cells, even within single tissues (Koliaraki et al., 2020; Krausgruber et al., 2020). Therefore, the consequence of global single-gene deletion models in mice may often not mirror what is happening at the tissue level. For example, IL-17 deficiency predisposes mice to age-associated obesity and impaired glucose tolerance but improves glucose uptake and insulin responses of adipocytes in vitro (Zuñiga et al., 2010). In addition, the actions of IL-17 are context dependent and may vary in physiological and pathological outcomes, leading to somehow contradictory IL-17–mediated metabolic regulation. Several examples are provided in Table 1. Of note, IL-17 signaling outcomes are not only influenced by the specificity of its target cells but also by concomitant signals from other cytokines present in the same environment. IL-17 is notorious for its ability to mediate synergistic or cooperative signaling with other cytokines or inflammatory stimuli (Li et al., 2019), which may constitute another compelling reason behind the pleiotropic roles of IL-17 on both local and systemic metabolism.

Beyond their well-established role in providing structural support to organs, epithelial and mesenchymal cells are actively involved in immune responses, which has become increasingly
feeds into the TCA cycle to generate ATP. Oxaloacetate and citrate are used for nucleotide and lipid synthesis, respectively. Fatty acids are metabolized through numerous ways. Glucose metabolism creates intermediates that supply different metabolic pathways. For example, pyruvate is converted to acetyl-CoA, which β-oxidation to acetyl-CoA, whereas glutamine is metabolized via glutaminolysis to α-ketoglutarate. Some metabolites (e.g., itaconate) directly influence IL-17 responses.

IL-17 activates downstream signaling pathways through distinct TRAF proteins. TRAF6 induces IkBζ, NF-κB, C/EBPs, and MAPK pathways. Together, these pathways upregulate transcription of IL-17-dependent target genes. Additionally, IL-17 controls posttranscriptional events that increase target mRNA levels through various RBPs (e.g., Act1, HuR, Arid5a, Regnase-1). IL-17 promotes stromal cell survival in lymph nodes (e.g., FRCs) through cell metabolic regulation involving an IkBζ-dependent increase in glycolysis and mitochondrial activity.

Metabolic regulation in IL-17–driven physiological responses

**IL-17–mediated metabolic regulation in barrier tissue**

IL-17 is a potent driver of barrier tissue repair (Zhao et al., 2020a), a metabolically demanding process (Eming et al., 2017). The regenerative role for IL-17 in the gut was inferred from patients with inflammatory bowel disease, whose symptoms were unexpectedly aggravated after clinical trials of anti–IL-17A/IL-17RA biologics for Crohn’s disease (Hueber et al., 2012; Targan et al., 2016). These observations were consistent with prior studies in mice showing that Act1, the essential IL-17R adaptor, promotes tissue repair in response to gut injury (Qian et al., 2007). Consistent with this, IL-17 neutralization or Il17a deficiency in mice caused exacerbated dextran sodium sulfate–induced intestinal injury (Ogawa et al., 2004; O’Connor et al., 2009; Lee et al., 2015). Similarly, IL-17 promotes wound healing in the skin, and impaired IL-17 in murine models of skin injury resulted in delayed wound closure, decreased barrier integrity, and skin microbiome dysbiosis (MacLeod et al., 2013; Floudas et al., 2017). Collectively, in homeostasis and acute models of inflammation, IL-17 promotes skin and gut tissue repair rather than drives pathogenic inflammation, as it does in psoriasis.

IL-17–dependent wound healing properties are explained by several mechanisms. IL-17 promotes proliferation of keratinocytes and epithelial cells via mitogenic signals, such as the ERK pathway (Shen et al., 2009; Zepp et al., 2017; Wu et al., 2015). Moreover, IL-17 induces expression of antimicrobial peptides (e.g., β-defensins, RegIIIγ, and S100A8/9; Lee et al., 2015; Whibley and Gaffen, 2015; MacLeod et al., 2013; Ha et al., 2014) and metalloinhibitor Steap4 (Wu et al., 2015), which promote proliferation (Lee et al., 2015; Whibley and Gaffen, 2015; MacLeod et al., 2013; Ha et al., 2014). Although the expression of genes associated with epithelial tight junction integrity was not modified in Il17a-deficient mice, IL-17 regulates cellular localization of the tight junction protein occludin proposed to underlie gut epithelial barrier function (Lee et al., 2015). In addition, synergistic signals mediated by other cytokines present in the local inflammatory milieu appear to tune IL-17–mediated tissue repair. Specifically, IL-17 synergizes with fibroblast growth factor 2 to induce genes that repair damaged epithelium.
In principle, IL-17–induced repair responses could be regulated by nutrient availability. Nevertheless, our understanding of how the different bioenergetic pathways (e.g., glycolysis, FAO) impact IL-17–mediated tissue repair and regeneration is still limited.

Although IL-17 signaling drives cell proliferation and tissue repair, this process may lead to tumorigenesis when dysregulated (Wang et al., 2014; Ernst and Putoczki, 2014; Zhang et al., 2017). Indeed, chronic inflammation is known to promote colorectal tumorigenesis (Terzić et al., 2010). In this context, IL-17 synergizes with TNF-α to induce an NF-κB– and HIF1α-dependent glycolytic pathway that promotes the survival and proliferation of cultured human colorectal cancer cells (Straus, 2013). IL-17 signaling in skin stem cells represents another example of the link between inflammation and tumorigenesis (Chen et al., 2019). In this setting, IL-17 promotes recruitment of epidermal growth factor receptor (EGFR) to the IL-17R complex in skin stem cells. This allows the phosphorylation of EGFR and subsequent activation of the ERK5 pathway, resulting in cell proliferation and wound-induced tumorigenesis (Chen et al., 2019). Accordingly, the cross talk between IL-17 and EGFR signaling in skin stem cells represents a surprisingly direct integration of IL-17 and growth factor signaling in tissue repair and tumorigenesis.

**Table 1. IL-17–driven metabolic pathways in health and disease**

| IL-17 target cells | Metabolic regulation | Cellular outcome | Organismal outcome | References |
|--------------------|----------------------|------------------|--------------------|------------|
| Epithelial cells/ Mesenchymal cells | Unknown | Proliferation | Tissue repair and wound healing | Lee et al. (2015), Song et al. (2015), MacLeod et al. (2013), Chen et al. (2019), Floudas et al. (2017) |
| Adipocytes | Decreased expression of proadipogenic TFs | Suppressed differentiation of adipocytes | Decreased adipose tissue mass accumulation | Ahmed and Gaffen (2013) |
| | Decreased insulin-mediated glucose uptake in vitro | Unknown | Unknown | Zúñiga et al. (2010) |
| | Increased expression of thermogenic genes | Enhanced metabolic respiration via uncoupled oxidative phosphorylation | Thermogenesis | Kohlgruber et al. (2018), Papotto and Silva-Santos (2018) |
| Stromal adipose cells | Unknown | IL-33 production | Insulin sensitivity | Kohlgruber et al. (2018), Papotto and Silva-Santos (2018) |

The metabolism-modulating activities of IL-17 are context dependent and may vary on the basis of its target cells.

et al., 2015). In principle, IL-17–induced repair responses could be regulated by nutrient availability. Nevertheless, our understanding of how the different bioenergetic pathways (e.g., glycolysis, FAO) impact IL-17–mediated tissue repair and regeneration is still limited.

Although IL-17 signaling drives cell proliferation and tissue repair, this process may lead to tumorigenesis when dysregulated (Wang et al., 2014; Ernst and Putoczki, 2014; Zhang et al., 2017). Indeed, chronic inflammation is known to promote colorectal tumorigenesis (Terzić et al., 2010). In this context, IL-17 synergizes with TNF-α to induce an NF-κB– and HIF1α-dependent glycolytic pathway that promotes the survival and proliferation of cultured human colorectal cancer cells (Straus, 2013). IL-17 signaling in skin stem cells represents another example of the link between inflammation and tumorigenesis (Chen et al., 2019). In this setting, IL-17 promotes recruitment of epidermal growth factor receptor (EGFR) to the IL-17R complex in skin stem cells. This allows the phosphorylation of EGFR and subsequent activation of the ERK5 pathway, resulting in cell proliferation and wound-induced tumorigenesis (Chen et al., 2019). Accordingly, the cross talk between IL-17 and EGFR signaling in skin stem cells represents a surprisingly direct integration of IL-17 and growth factor signaling in tissue repair and tumorigenesis.

**IL-17–mediated metabolic regulation in nonbarrier tissue**

It has long been noted that mice lacking IL-17R or IL-17A are overweight, gaining fat mass with age (Zúñiga et al., 2010; Goswami et al., 2009; Ahmed and Gaffen, 2010). These observations were consistent with prior studies investigating the role of IL-17 in osteoporosis, where IL-17 was shown to suppress mesenchymal differentiation of adipocytes and promote differentiation of osteoblasts (Shin et al., 2009; Huang et al., 2009). These studies support a model in which lack of IL-17 establishes an environment where adipogenesis is favored. Mechanistically, IL-17 activation of a preadipocyte model cell line suppressed expression of proadipogenic transcription factors (TFs; e.g., CCAAT enhancer binding protein [C/EBP]-α, PPARγ, and Krüppel-like factor [KLF] 5) while enhancing antiadipogenic TFs (e.g., KLF2, KLF3; Ahmed and Gaffen, 2013). Thus, IL-17 restrains...
IL-17 contributes to the homeostatic regulation of glucose metabolism as well (Zúñiga et al., 2010). In vitro, IL-17 inhibited insulin-induced glucose uptake by adipocytes (Zúñiga et al., 2010). The capacity of IL-17 to regulate glucose homeostasis was further confirmed in vivo. Indeed, young IL-17–deficient mice present with slightly increased fasting glucose levels, lower insulin levels, and improved glucose clearance upon glucose tolerance test (Zúñiga et al., 2010), an effect that was lost upon development of age-associated obesity (Zúñiga et al., 2010). Like IL-17, the effects of IL-6 on glucose metabolism are context dependent, leading to both positive (improved insulin sensitivity) and negative (impaired glucose tolerance) outcomes (Hotamisligil, 2017b). In contrast to IL-17 and IL-6, the metabolic effects of TNF-α are highly consistent among mouse models, where neutralization of TNF-α results in increased insulin sensitivity (for a complete list, see https://www.metaflammation.org; Borst et al., 2004; Araújo et al., 2007; Hotamisligil, 2017b).

Adaptive thermogenesis is the process of heat production, mainly in brown adipose tissue (BAT), and recent evidence shows that IL-17 contributes to this process. Thermogenesis is mediated by uncoupling protein 1 (UCP1), which uncouples mitochondrial FAO from ATP production, thereby releasing the energy of substrate oxidation as heat (Chouchani et al., 2019). In addition, BAT is richly innervated by sympathetic nerves, which release norepinephrine upon external stimuli (e.g., cold), and consequently activate lipolysis and thermogenic regulation (Chouchani et al., 2019). In this context, a homeostatic adipose population of IL-17–secreting γδ-T cells is required for the maintenance of body temperature (Kohlgruber et al., 2018; Papotto and Silva-Santos, 2018). IL-17 and TNF-α signaling in BAT trigger expression of UCP1, driving adaptive thermogenesis (Fig. 3). Consistent with this, IL-17–deficient mice are susceptible to hypothermia as demonstrated by decreased expression of thermogenic genes (e.g., Ucp1) and a failure to increase energy expenditure after cold challenge (Kohlgruber et al., 2018; Papotto and Silva-Santos, 2018). A related study found that IL-17F, rather than IL-17A, impacted thermogenesis. IL-17F was suggested to promote expression of TGF-β1 in adipocytes, which in turn supported sympathetic innervation of adipose tissue and hence activated lipolysis and thermogenesis via norepinephrine (Ciofani, 2020; Hu et al., 2020). Accordingly, these studies point to intriguing cross talk between IL-17 and adipose tissue in homeostatic body temperature control (Fig. 3).

In addition to its role in regulating adipogenesis and energy homeostasis, IL-17 mediates metabolic-immunological coordination in adipose tissue. In aging mice, the number of IL-17–producing γδ-T cells increase concomitantly with T reg cells in adipose tissue (Fig. 3; Kohlgruber et al., 2018; Papotto and Silva-Santos, 2018). Consequently, Il17a−/− mice show a decrease in T reg cell numbers in fat, suggesting that IL-17 is implicated in homeostatic expansion of T reg cells (Kohlgruber et al., 2018; Papotto and Silva-Santos, 2018). This effect is thought to be initiated by IL-17 and TNF-α signaling in adipose stromal cells leading to IL-33 production (Kohlgruber et al., 2018; Papotto and Silva-Santos, 2018), thereby maintaining the expansion of T reg cells expressing the IL-33 receptor (ST2). Although these studies did not report the consequences of IL-17–mediated T reg cell accumulation on insulin sensitivity (Mathis, 2019), T reg cells are known to promote this process (Feuerer et al., 2009; Kolodin et al., 2015). Hence, the ability of stromal adipose tissue to...
provide a niche that supports T reg cell differentiation reveals that mesenchymal-immune interactions are not restricted to lymphoid organs but can also happen in peripheral tissues.

A key question that emerges from these explorations of IL-17 in adipose tissue is the impact on human obesity and metabolic disorders, such as diabetes. Is there any advantage for IL-17-mediated metabolic-immune regulation in adipose tissue? One could speculate that the increase in IL-17 production observed in metabolic syndrome (Ahmed and Gaffen, 2010; Sumarac-Dumanovic et al., 2009) may be viewed as an attempt from the immune system to correct the metabolic disorders associated with the increase in fat storage and insulin resistance. Indeed, by inhibiting adipogenesis and promoting T reg cell expansion, IL-17 may play a beneficial role in maintaining insulin sensitivity and limiting inflammation in adipose tissue. However, obesity-linked metabolic diseases, such as type 2 diabetes and cardiovascular diseases, are associated with chronic low-grade inflammation (Mathis and Shoelson, 2011; Donath and Shoelson, 2011). Therefore, once obesity is established, the beneficial metabolic effects of IL-17 may be offset by other detrimental mechanisms (e.g., high levels of TNF-α), shifting the balance toward inflammation and leading to obesity-associated metabolic complications.

Metabolic regulation in IL-17–driven pathological responses

IL-17 and cellular immunometabolism during inflammation

Psoriasis is considered a metabolism-associated disease, but the impact of metabolic changes in the main IL-17 target cells in this disease—keratinocytes—are not fully understood (Pohl et al., 2020; Harden et al., 2016; Kamleh et al., 2015; Herbert et al., 2018; Zhang et al., 2018; Kang et al., 2017). It has been shown that arginase-1, a catalytic enzyme in the urea cycle, is upregulated in skin from psoriatic patients (Bruch-Gerharz et al., 2003). Interestingly, IL-17 downregulates protein phosphatase 6, a regulatory signaling intermediate, resulting in increased arginase-1 expression in psoriatic keratinocytes (Lou et al., 2020; Bandyopadhyay and Larregina, 2020). Accumulation of arginase-1 increases polyamine production from the urea cycle, which then binds to self-RNA-antigen complexes released by damaged keratinocytes. Consequently, these complexes seem to act as danger signals and activate dermal dendritic cells to produce proinflammatory cytokines. In particular, dendritic cell–derived IL-6 promotes IL-17 secretion. Therefore, arginase-1 activation maintains a positive feedback loop that sustains inflammation in psoriatic skin. Consistently, inhibition of arginase-1 ameliorates skin inflammation in imiquimod (IMQ)-induced experimental dermatitis, a common mouse model of psoriasis (Lou et al., 2020; Bandyopadhyay and Larregina, 2020).

Another study showed that IL-17 induces cholesterol accumulation in keratinocytes, leading to secretion of proinflammatory cytokines (Varshney et al., 2016). However, in contrast to IL-17–mediated reprogramming of the urea cycle, our knowledge on how IL-17 induces its target genes through regulation of cholesterol metabolism is quite limited. Collectively, IL-17–mediated metabolic regulation in keratinocytes is a key component of a coordinated ensuing immune response.

During rheumatoid arthritis (RA), SFs expand, become invasive, and promote joint inflammation, thereby destroying cartilage and promoting development of the hyperplastic RA synovium as a tertiary lymphoid organ (Nygaard and Firestein, 2020). During this process, the metabolism of SFs is “re-programmed” as a consequence of the inflamed microenvironment (Bustamante et al., 2017). This metabolic switch in the RA synovium is characterized by mitochondrial dysfunction (Bustamante et al., 2017; Harty et al., 2012; Biniecka et al., 2016) and disruption of glucose metabolism (Bustamante et al., 2018; de Oliveira et al., 2019). In SFs, IL-17 decreases expression of oxidative phosphorylation component genes and, consequently, induces autophagy and inhibition of cell death (Kim et al., 2017; Bustamante et al., 2017; Clarke and Simon, 2019). Thus, activated fibroblasts shift from oxidative phosphorylation to glycolytic ATP production, and therefore, inhibition of glycolysis decreases cell proliferation, migration, and invasion (de Oliveira et al., 2019; Bustamante et al., 2018). Moreover, IL-17 induces expression of the amino acid transporter LAT1 in SFs, resulting in enhanced leucine uptake and potentiated cell migratory capacity (Yu et al., 2018). Accordingly, IL-17–activated SFs upregulate the expression of nutrient transporters to perpetuate inflammation. However, the efficacy of IL-17 blockade in treating RA was disappointingly modest (Taams, 2020; Genovese et al., 2014; Mease et al., 2018; Pavelka et al., 2015). Although the reasons remain unclear, RA is a heterogeneous disease, and not all patients present with high IL-17 levels; thus, IL-17 blockade alone may not be sufficient to disrupt all the requisite inflammatory triggers effectively (Taams, 2020). Moreover, effects of IL-17 may be temporal in early versus late disease, an issue difficult to address in standard RA clinical trials (Taams, 2020).

FRCs are specialized cells located in the T cell areas of lymphoid organs that produce collagen-rich reticular fibers to support immune cell organization (Jalkanen and Salmi, 2020; Krishnamurty and Turley, 2020; Kiliaraki et al., 2020). However, FRCs not only provide structural support to immune cells but also actively participate in determining the magnitude of immune responses as well as immune cell trafficking and peripheral tolerance (Jalkanen and Salmi, 2020; Krishnamurty and Turley, 2020; Kiliaraki et al., 2020). Interestingly, recent studies demonstrated an unexpected role for IL-17 in driving metabolic regulation in FRCs during experimental autoimmune settings, including experimental autoimmune encephalomyelitis (EAE) and colitis (Majumder et al., 2019). Like stromal cells in the RA synovium, IL-17 promotes proliferation and survival of FRCs by increasing metabolic fitness. Majumder et al. (2019) showed that IL-17 drives these effects at least in part through induction of the Cpt1a gene, a rate-limiting enzyme of mitochondrial FAO, which was driven by the IkBα TF (Fig. 2 C). Consistently, FRCs fail to expand in mice lacking IL-17RA in FRCs during EAE. Moreover, these mice show compromised B-cell activation and autoantibody production (Majumder et al., 2019; Bordon, 2019; Mueller, 2019). Thus, IL-17 drives successful metabolic reprogramming of FRC, which allows activation of the adaptive immune response. In contrast to SFs where IL-17–mediated metabolic regulation is detrimental, IL-17–driven
metabolic changes in FRCs may have more broad consequences in a context-dependent manner.

**IL-17 and organismal immunometabolism during inflammation**

Autoimmune diseases such as psoriasis and RA are often accompanied by impacts on the cardiovascular system, and emerging data illustrate how far reaching these consequences can be (Davidovici et al., 2010; Gisondi et al., 2018; Ferguson et al., 2019; Frostaegard, 2005; Katz et al., 2019; Liu and Kaplan, 2018). However, the mechanisms underlying autoimmunity-associated cardiovascular consequences are largely unknown. Even so, recent studies provide interesting mechanistic insights. In IMQ-induced experimental psoriasis, IL-17 was found to promote collagen deposition in psoriatic lesions and distal skin regions and arteries, thereby altering lipoprotein traffic. Consequently, lipoproteins accumulate within the vessel wall, promoting atherosclerosis. IL-17 neutralization rescued lipoprotein transit, suggesting a therapeutic avenue for treating this complication (Huang et al., 2019). These observations are consistent with other studies in mouse models of psoriasis where IL-17 was linked to thrombosis and where IL-17 neutralization reduced skin and cardiovascular manifestations (Li et al., 2018). Cumulatively, these studies suggest that treating the noncardiovascular symptoms of autoimmunity may be effective in reducing cardiovascular comorbidity. Nevertheless, a recent case-time-control study suggested that the administration of ustekinumab, which blocks the IL-12/IL-23 p40 subunit, may trigger severe cardiovascular events among patients at high cardiovascular risk (Herjan et al., 2018). Strikingly, the Arid5a and Regnase-1, two IL-17 transcriptional targets of NF-κB (Nfkb) is a noncanonical member of the NF-κB family (Karlsen et al., 2010; Yamazaki et al., 2005). IκBκ is now recognized to be a vital mediator of many IL-17 metabolic activities (Fig. 2 C). As noted, IL-17 induction of IκBκ in FRCs drives expression of Cptta and is required for elevated glucose uptake needed to support cell survival (Mueller, 2019; Majumder et al., 2019). IκBκ is implicated in psoriasis both genetically and functionally (Tsai et al., 2015; Johansen et al., 2015), and Nfkbi is deficient in mice, similar to IL-17-deficient mice, are resistant to pathology in IMQ dermatitis (Johansen et al., 2015). Notably, in keratinocytes, IL-17-mediated induction of IκBκ and its downstream target genes is blocked by a derivative of itaconate (Bambouskova et al., 2018; Bordon, 2018), a metabolite from the TCA cycle (Fig. 2 A; O’Neill and Artyomov, 2019). Hence, itaconate-mediated regulation of IκBκ represents a striking example of how a standard metabolic pathway can exert immunoregulatory potential (Bambouskova et al., 2018; Bordon, 2018).

From the perspective of downstream IL-17 signaling, IκBκ is at a nexus of not only transcriptional events but also posttranscriptional events. It has become increasingly apparent that a major mechanism by which IL-17 mediates gene expression is through stabilization/destabilization of inflammatory mRNAs and control of translation (Herjan et al., 2013; Amatya et al., 2018; Monin et al., 2017; Garg et al., 2015; Tanaka et al., 2019; Herjan et al., 2018). Strikingly, the Nfkbi mRNA encoding IκBκ is intrinsically unstable. Nfkbi is subject to posttranscriptional regulation by Arid5a and Regnase-1, two IL-17–induced RNA-binding proteins that constrain fibrosis (Ramani et al., 2018). Therefore, IL-17 function in tissue remodeling is influenced by the responding cell type and the local inflammatory environment. Metabolic perturbation is increasingly appreciated as an important pathogenic process that underlies fibrosis, with upregulation of glycolysis favoring ECM deposition over degradation (Zhao et al., 2019; Rabinowitz and Mutlu, 2019; Zhao et al., 2020b). TGF-β is a well-known activator of glycolysis in mesenchymal cells, leading to collagen synthesis (Zhao et al., 2020b; Jiang et al., 2015). Considerable data show that the IL-17A–TGF-β axis is important to the development of fibrosis (Wilson et al., 2010; Fabre et al., 2014). Hence, understanding the metabolic milieu that sustains IL-17–mediated fibrosis might offer new therapeutic avenues for treating fibrosis.

**Metabolic pathways as potential therapeutic targets in IL-17–driven pathology**

**Metabolic regulation of IL-17 signaling**

Cellular metabolism is not just limited to the delivery of energy and substrates for biosynthesis but can regulate downstream signaling by cytokines. IL-17 signaling events are initiated by the multifunctional adaptor protein Act1, which is recruited to the IL-17R after ligand engagement. Act1 in turn recruits diverse TNF receptor–associated factor (TRAP) proteins, which initiate transcriptional and posttranscriptional pathways (Fig. 2 B; Gaffen, 2009; Amatya et al., 2017; Li et al., 2019; Qian et al., 2007). IL-17 signaling is well known to activate the classical NF-κB pathway. Additional downstream IL-17 TFs include C/EBP and AP-1 components ( Shen et al., 2006; Ruddy et al., 2004; Patel et al., 2007; Karlsen et al., 2010; Slowikowski et al., 2020; Qian et al., 2007; Chang et al., 2006; Shen et al., 2009). A major transcriptional target of NF-κB is IκBκ (Nfkbi), a noncanonical member of the NF-κB family (Karlsen et al., 2010; Yamazaki et al., 2005). IκBκ is now recognized to be a vital mediator of many IL-17 metabolic activities (Fig. 2 C). As noted, IL-17 induction of IκBκ in FRCs drives expression of Cptta and is required for elevated glucose uptake needed to support cell survival (Mueller, 2019; Majumder et al., 2019). IκBκ is implicated in psoriasis both genetically and functionally (Tsai et al., 2015; Johansen et al., 2015), and Nfkbi is/− mice, similar to IL-17-deficient mice, are resistant to pathology in IMQ dermatitis (Johansen et al., 2015). Notably, in keratinocytes, IL-17–mediated induction of IκBκ and its downstream target genes is blocked by a derivative of itaconate (Bambouskova et al., 2018; Bordon, 2018), a metabolite from the TCA cycle (Fig. 2 A; O’Neill and Artyomov, 2019). Hence, itaconate-mediated regulation of IκBκ represents a striking example of how a standard metabolic pathway can exert immunoregulatory potential (Bambouskova et al., 2018; Bordon, 2018).
proteins (RBPs) that play opposing roles in determining mRNA longevity (Fig. 2 B). Whereas Regnase-1 is an endoribonuclease that degrades Nfkbi mRNA (Garg et al., 2015), ArID5a binds to a similar site and promotes Nfkbi stability and, hence, total protein levels (Amatya et al., 2018). By these means, posttranscriptional regulation pathways activated by IL-17 exhibit cross talk with transcriptional signaling. Hence, regardless of the mechanism by which IL-17 target genes are upregulated transcriptionally, RBPs can regulate their expression by controlling the stability/translation of TFs such as IκB. Nevertheless, it is still not clear how IL-17-mediated posttranscriptional events are integrated with its broader signaling to generate metabolic responses or, conversely, how metabolic intermediates influence RBP function.

**Metabolic regulation of Th17 cells**

Cellular metabolism may affect IL-17 activity by acting upstream via Th17 cell differentiation and proliferation (O’Neill et al., 2016; Shi et al., 2011). For instance, FAS in Th17 cells generates RORγt ligands, which favor IL-17 production over IL-10, as demonstrated in in vitro T cell differentiation experiments as well as during EAE (Wang et al., 2015; Gaublomme et al., 2015; Davis et al., 2015). In addition, the balance between Th17 and T reg cells is determined by FAO. T reg cells exhibit increased FAO gene expression (e.g., Cptla) compared with other T cells (Michalek et al., 2011; Gerriets et al., 2015). Numerous studies demonstrated that the glycolytic pathway affects Th17 cell differentiation (Shi et al., 2011; Woodman, 2011; Revu et al., 2018; DiToro et al., 2020). Specifically, under Th17 cell-polarizing conditions, mammalian target of rapamycin upregulates HIF1α, which is not observed in Th1 or Th2 cells. HIF1α promotes increased glycolysis and enhances IL-17 production, whereas deficiency in HIF1α diverts cells toward a T reg cell profile (Shi et al., 2011; Woodman, 2011). Moreover, Th17 cell differentiation is maintained by the conversion of glutamate-derived α-ketoglutarate (Fig. 2 A) into 2-hydroxyglutarate, promoting Foxp3 methylation and silencing (Xu et al., 2017; Pearce and Pearce, 2018). Thus, metabolism dictates T cell fate via epigenetic regulation. Cumulatively, modulation of glycolytic pathway, lipid metabolism, or glutamate-dependent metabolic pathway could affect Th17 cell differentiation, possibly offering therapeutic avenues to treat certain autoimmune conditions. Therefore, it may be useful to consider the effects of metabolic alterations on both Th17 cells and IL-17 signaling targets when designing therapeutic strategies. Indeed, small molecules, such as dimethylfumarate, used to treat psoriasis and multiple sclerosis, downregulate aerobic glycolysis in Th17 cells (Kornberg et al., 2018, Angiari and O’Neill, 2018) as well as dampen IL-17–induced IκB expression in keratinocytes (Ohgakuchi et al., 2020). As we learn more about the implication of cellular metabolic processes in inflammation, novel therapeutic opportunities are likely to be revealed for the treatment of IL-17–related immune disorders.

**Conclusion and perspectives**

This review highlights a facet of IL-17 function that has been underappreciated until quite recently. IL-17 is best known as a critical host-defensive cytokine against extracellular fungal and bacterial species in conjunction with its widely accepted proinflammatory role. However, IL-17 is not simply a proinflammatory cytokine, and the above-described studies pointed to an emerging role of IL-17 signaling in metabolism at the cellular, tissue, and organismal level. In addition, cellular metabolism can influence IL-17 signal transduction. During inflammation, a feed-forward loop appears to be set in motion wherein effector molecules released from IL-17 target cells modulate systemic metabolism, in turn regulating the metabolism and function of IL-17 target cells.

Metabolism is integrated into the protective and pathogenic aspects of IL-17 responses (Fig. 1), and it is likely that some transcriptional regulators (e.g., IκB) that are central to IL-17 signaling activities also control specific metabolic programs that support this cytokine’s functions. In addition, cellular metabolism may impact gene expression through epigenetic modifications, and chromatin-modifying enzymes require different metabolites as cofactors or substrates (Montellier and Gaucher, 2019; Lio and Huang, 2020). Hence, a future challenge will be to define the relationships between IL-17–mediated metabolic regulation and epigenetics or chromatin remodeling. Such epigenetic changes may in turn be the basis of chronic, sustained transcriptional responses that are seen in autoimmune settings, which thereby modulate the activity of IL-17 and related proinflammatory cytokine programs.

**Acknowledgments**

Figures were made using BioRender.

S.L. Gaffen was supported by National Institutes of Health grant AI47383 and the Rheumatology Research Foundation. M.J. McGeachy was supported by National Institutes of Health grant AI48356.

Author contributions: Conceptualization: R. Bechara and S.L. Gaffen; Writing – original draft: R. Bechara; Writing – review and editing: S.L. Gaffen and M.J. McGeachy; Funding acquisition: S.L. Gaffen; Supervision: S.L. Gaffen.

Disclosures: The authors declare no competing interests exist.

Submitted: 21 October 2020
Revised: 8 January 2021
Accepted: 25 February 2021

**References**

Ahmed, M., and S.L. Gaffen. 2010. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev. 21:449–453. https://doi.org/10.1016/j.cytogfr.2010.10.005

Ahmed, M., and S.L. Gaffen. 2013. IL-17 inhibits adipogenesis in part via C/EBPα, PPARγ and Krüppel-like factors. Cytokine. 61:898–905. https://doi.org/10.1016/j.cyto.2012.12.007

Amatya, N., A.V. Garg, and S.L. Gaffen. 2017. IL-17 signaling: The yin and the yang. Trends Immunol. 38:310–322. https://doi.org/10.1016/j.it.2017.01.006

Amatya, N., E.E. Childs, J.A. Cruz, F.E.Y. Aggor, A.V. Garg, A.J. Berman, J.E. Gudjonsson, U. Atasoy, and S.L. Gaffen. 2018. IL-17 integrates multiple self-reinforcing, feed-forward mechanisms through the RNA binding protein ArID5a. Sci. Signal. 11:eaa14617. https://doi.org/10.1126/scisignal.aai4617
Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman. 1993. Adipose ex-
Gisondi, P., A.C. Fostini, I. Foss`a, G. Girolomoni, and G. Targher. 2018. Pso-
Hotamisligil, G.S. 2017a. Foundations of immunometabolism and im-
Harty, L.C., M. Biniecka, J. O
Herbert, D., S. Franz, Y. Popkova, U. Anderegg, J. Schiller, K. Schwede, A.
Hu, B., C. Jin, X. Zeng, J.M. Resch, M.P. Jedrychowski, Z. Yang, B.N. Desai,
Ishigame, H., S. Kakuta, T. Nagai, M. Kadoki, A. Nambu, Y. Komiyama, N.
Hueber, W., B.E. Sands, S. Lewitzky, M. Vandemeulebroeke, W. Reinisch,
Injarabian, L., A. Devin, S. Ransac, and B.S. Marteyn. 2019. Neutrophil met-
Hu, B., C. Jin, X. Zeng, J.M. Resch, M.P. Jedrychowski, Z. Yang, B.N. Desai,
Ishida, M., T. Jonasson, W. Liu, P. Martin, M. Tuder, M. Ovbiagelesi, et al. 2016.
Hansen, A.B., L. Verhees, C. Jørgensen, S. Kramer, T. Paiva, M. T. Santibáñez,
Ha, H.L., H. Wang, P. Pisitkun, J.C. Kim, I. Tassi, W. Tang, M.I. Morasso, M.C.
Hueber, W., B.E. Sands, S. Lewitzky, M. Vandemeulebroeke, W. Reinisch,
Intrigiani, R., A. Crisma, A. Francavilla, F. Giorda, A. D'Antonio, et al. 2015. IL-
Harty, L.C., M. Biniecka, J. O
Herbert, D., S. Franz, Y. Popkova, U. Anderegg, J. Schiller, K. Schwede, A.
Hu, B., C. Jin, X. Zeng, J.M. Resch, M.P. Jedrychowski, Z. Yang, B.N. Desai,
Ishigame, H., S. Kakuta, T. Nagai, M. Kadoki, A. Nambu, Y. Komiyama, N.
metabolic changes in psoriasis lesional skin. Sci. Rep. 10:3081. https://doi.org/10.1038/s41598-020-59996-z
Polaj, M., D. Nowak, B. Le Nault, C. Droitcourt, M.D. Drici, E. Shidian, B. Guillot, H. Bachelez, H. Ait-Oufella, et al. 2020. Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12/23p40 antibody ustekinumab. JAMA Dermatol. 156:1208. https://doi.org/10.1001/jamadermatol.2020.2977
Prinz, I., L. Sandrock, and U. Mrowietz. 2020. Interleukin-17 cytokines: Effectors in psoriasis-A breakthrough in understanding and treatment. J. Exp. Med. 217:e2019248. https://doi.org/10.1084/jem.20191397
Qian, Y., C. Liu, J. Hartупee, C.Z. Altuntas, M.F. Guleн, D. Jane-Wit, J. Xiao, Y. Lu, N. Gilti, J. Liu, et al. 2007. The adaptor Act1 is required for interleukin-17-dependent signaling associated with autoimmune and inflammatory disease. Nat. Immunol. 8:247-256. https://doi.org/10.1038/ni1439
Rabinowitz, J.D., and G.M. Muhl. 2019. A metabolic strategy to reverse fibrosis? Nat. Metab. 1:12-13. https://doi.org/10.1038/s42255-018-0013-8
Rammori, R.J., T. Zhou, B.M. Coleman, C.V. Jawale, Y. Liu, and P.S. Biswas. 2018. IL-17 receptor signaling negatively regulates the development of tubulointerstitial fibrosis in the kidney. Mediators Inflamm. 2018:1563072. https://doi.org/10.1155/2018/1563072
Revu, S., J. Wu, M. Henkel, N. Rittenhouse, A. Menk, G.M. Delgoffe, A.C. Bechara et al. Journal of Experimental Medicine. IL-17 regulates cellular and tissue metabolism https://doi.org/10.1084/jem.20202191
Spallanzani, R.G., D. Zemmour, T. Xiao, T. Jayewickreme, C. Li, P.J. Bryce, C. Benoist, and D. Mathis. 2019. Distinct immuneocyte-promoting and adenosine-producing stromal components coordinate adipose tissue immune and metabolic tenors. Sci. Immunol. 4:eaaw3668. https://doi.org/10.1126/sciimmunol.aaw3668
Straus, D.S. 2013. TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol. Cancer. 12:78. https://doi.org/10.1186/1476-4598-12-78
Sumarcan-Dumanovic, M., D. Stevanovic, A. Ljubic, J. Jorga, M. Simic, D. Stamenkovic-Pejkovic, V. Starcevic, V. Trajkovic, and D. Misch. 2009. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int. J. Obes. 33:151-156. https://doi.org/10.1038/ijo.2008.216
Taams, L.S. 2020. Interleukin-17 in rheumatoid arthritis: Trials and tribulations. J. Exp. Med. 217:e2019248. https://doi.org/10.1084/jem.20192048
Taleb, S., M. Romain, B. Ramkhelawon, C. Uyttenhove, G. Pasterkamp, O. Herbin, B. Esposito, N. Perez, H. Yasukawa, J. Van Snick, et al. 2009. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 206:2067-2077. https://doi.org/10.1084/jem.20090545
Tanaka, H., Y. Arima, D.kimamura, Y. Tanaka, N. Takahashi, T. Uehata, K. Maeda, T. Sato, M. Murakami, and S. Akira. 2019. Phosphorylation-dependent Regnase-1 release from endoplasmic reticulum is critical in IL-17 response. J. Exp. Med. 216:1431-1449. https://doi.org/10.1084/jem.20181078
Targan, S.R., B. Feagan, S. Vermeire, P. Panaccione, G.Y. Melmed, C. Landers, D. Li, C. Russell, R. Newmark, N. Zhang, et al. 2016. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am. J. Gastroenterol. 111:1599-1607. https://doi.org/10.1038/ajg.2016.298
Terzic, J., S. Grivennikov, E. Karin, and M. Karin. 2010. Inflammation and colon cancer. Gastroenterology. 139:2101-2114.e5. https://doi.org/10.1053/j.gastro.2010.01.058
Troha, K., and J.S. Ayres. 2020. Metabolic adaptations to infections at the organismal level. Trends Immunol. 41:113-125. https://doi.org/10.1016/j.it.2019.12.001
Tsoi, L.C., S.L. Spain, E. Ellingshaus, P.E. Stuart, F. Capon, J. Knight, T. Tejaveji, H.M. Kang, M.H. Allen, S. Lambert, et al. 2015. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat. Commun. 6:7001. https://doi.org/10.1038/ncomms8001
Tuong, Z.K., and M.R. Cattalothy. 2020. Organ immune responses - don’t forget the structural cells. Nat. Rev. Nephrol. 16:570-571. https://doi.org/10.1038/s41581-020-00334-x
Vansanakhum, A., K. Moro, A. Xin, Y. Liao, R. Gloury, S. Kawamoto, S. Fagarasan, L.A. Mielke, S. Afshar-Sterle, S.L. Masters, et al. 2015. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat. Immunol. 16:276-285. https://doi.org/10.1038/ni.3085
Vats, D., L. Mukundan, J.I. Oegaard, L. Zhang, K.L. Smith, C.R. Morel, R.A. Wagner, D.R. Greaves, P.J. Murray, and A. Chawla. 2006. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab. 4:33-24. https://doi.org/10.1016/j.cmet.2006.05.011
Veldhoen, M. 2017. Interleukin 17 is a chief orchestrator of immunity. Nat. Rev. Immunol. 17:412-422. https://doi.org/10.1038/nri.2016.186
Verma, A.H., J.P. Richardson, C. Zhou, B.M. Coleman, D.L. Moyes, J. Ho, A.R. Huippler, K. Ramanali, M.J. McGeachy, I.A. Mufazalov, et al. 2017. Oral epithelial cells orchestrate innate type 17 responses to Candida albicans through the virulence factor candidin. Sci. Immunol. 2:eaam8834. https://doi.org/10.1126/sciimmunol.aam8834
Vitiello, G.A., and G. Miller. 2020. Targeting the interleukin-17 immune axis for cancer immunotherapy. J. Exp. Med. 217:e20190456. https://doi.org/10.1084/jem.20190456
Wang, K., M.K. Kim, G. Di Caro, J. Wong, S. Shalapour, J. Wan, W. Zhang, Z. Zhong, E. Sanchez-Lopez, L.W. Wu, et al. 2014. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumor-microgenesis. Immunity. 41:1052-1063. https://doi.org/10.1016/j.immuni.2014.11.009
Wang, C., N. Yosef, J. Gaulbomme, C. Wu, Y. Lee, C.B. Clish, J. Kaminski, S. Wilson, M.S., S.K. Madala, T.R. Ramalingam, B.R. Gochuico, I.O. Rosas, A.W. Cheever, and T.A. Wynn. 2010. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207:535-552. https://doi.org/10.1084/jem.200920121

Bechara et al.

IL-17 regulates cellular and tissue metabolism

Journal of Experimental Medicine

https://doi.org/10.1084/jem.20202191
Winer, S., G. Paltser, Y. Chan, H. Tsui, E. Engleman, D. Winer, and H.M. Dosch. 2009. Obesity predisposes to Th17 bias. Eur. J. Immunol. 39: 2629–2635. https://doi.org/10.1002/eji.200838893

Woodman, I. 2011. T cells: a metabolic sHIFt to turn 17. Nat. Rev. Immunol. 11: 503. https://doi.org/10.1038/nri3037

Wu, L., X. Chen, J. Zhao, B. Martin, J.A. Zepp, J.S. Ko, C. Gu, G. Cal, W. Ouyang, G. Sen, et al. 2015. A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis. J. Exp. Med. 212:1571–1587. https://doi.org/10.1084/jem.20150204

Yamazaki, S., T. Muta, S. Matsuo, and K. Takeshige. 2005. Stimulus-specific induction of a novel nuclear factor-kappaB regulator, IkappaB-zeta, via Toll/Interleukin-1 receptor is mediated by mRNA stabilization. J. Biol. Chem. 280:1678–1687. https://doi.org/10.1074/jbc.M409983200

Yu, Z., W. Lin, Z. Rui, and P. Jihong. 2018. Fibroblast-like synoviocyte migration is enhanced by IL-17-mediated overexpression of L-type amino acid transporter 1 (LAT1) via the mTOR/4E-BP1 pathway. Amino Acids. 50:331–340. https://doi.org/10.1007/s00726-017-2520-4

Zepp, J.A., J. Zhao, C. Liu, K. Bulek, L. Wu, X. Chen, Y. Hao, Z. Wang, X. Wang, W. Ouyang, et al. 2017. IL-17A-induced PLET1 expression contributes to tissue repair and colon tumorigenesis. J. Immunol. 199:3849–3857. https://doi.org/10.4049/jimmunol.1601540

Zhang, J., Q. Fu, Z. Ren, Y. Wang, C. Wang, T. Shen, G. Wang, and L. Wu. 2015. Changes of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosis. Gynecol. Endocrinol. 31: 183–190. https://doi.org/10.3109/09513590.2014.975683

Zhao, X., P. Psarianos, L.S. Ghorasle, K. Yip, D. Goldstein, R. Gilbert, I. Witterick, H. Pang, A. Hussain, J.H. Lee, et al. 2019. Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis. Nat. Metab. 1:147–157. https://doi.org/10.1038/s42255-018-0008-5

Zhao, X., J. Chen, T. Heejan, and X. Li. 2020a. The role of interleukin-17 in tumor development and progression. J. Exp. Med. 217:e20190297. https://doi.org/10.1084/jem.20190297

Zhao, X., J.Y.Y. Kwan, K. Yip, P.P. Liu, and F.F. Liu. 2020b. Targeting metabolic dysregulation for fibrosis therapy. Nat. Rev. Drug Discov. 19:57–75. https://doi.org/10.1038/s41573-019-0040-5

Zúñiga, L.A., W.J. Shen, B. Joyce-Shaikh, E.A. Pyatnova, A.G. Richards, C. Thom, S.M. Andrade, D.J. Cua, F.B. Kraemer, and E.C. Butcher. 2010. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J. Immunol. 185:6947–6959. https://doi.org/10.4049/jimmunol.1001269